Literature DB >> 12526069

Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.

Ricardo Kogan1, M Angélica Martínez, Lilian Rubilar, Ernesto Payá, Ilsa Quevedo, Homero Puppo, Guido Girardi, José A Castro-Rodriguez.   

Abstract

Our objective was to compare the clinical efficacy of azithromycin vs. erythromycin and amoxicillin in the treatment of presumed bacterial community-acquired pneumonia in ambulatory children, and to evaluate the etiologies of these illnesses. One hundred and ten children, aged 1 month to 14 years, were enrolled between January 1996-January 1999. Children were distributed into two groups according to clinical and radiological patterns: classic or atypical pneumonia. Patients with classic pneumonia were randomly assigned to receive oral amoxicillin 75 mg/kg/day for 7 days, or azithromycin 10 mg/kg/day for 3 days; patients with atypical pneumonia received azithromycin 10 mg/kg/day for 3 days, or erythromycin 50 mg/kg/day for 14 days. Chest X-ray, clinical, and laboratory parameters were obtained on enrollment. Clinic visits were performed on days 3, 7, and 14, and chest X-ray follow-up on days 7 and 14. Microbiological diagnosis of classic pathogens was based on blood and bronchial secretion cultures. The diagnosis of atypical pathogens C. pneumoniae, C. trachomatis, and M. pneumoniae was based on PCR and serologic tests.Forty-seven children met the criteria for classic pneumonia (23 children received azithromycin, and 24 received amoxicillin), and 59 children had atypical pneumonia (33 children were treated with azithromycin, and 26 with erythromycin). Demographic characteristics at enrollment were similar between children with classic pneumonia treated with azithromycin and erythromycin and children treated with azithromycin and erythromycin for atypical pneumonia. However, on day 7, children with classic pneumonia who received azithromycin normalized their chest X-ray more often than those who received amoxicillin (81.0% vs. 60.9%, respectively, P = 0.009). The same was true for children with atypical pneumonia; their chest X-rays had normalized by day 14 (100% in those with azithromycin vs. 81% in those with erythromycin, P = 0.059). Also, children with atypical pneumonia treated with azithromycin had earlier cessation of cough than children treated with erythromycin (3.6 +/- 1.9 vs. 5.5 +/- 3.6 days respectively, P = 0.02). There were only three children with side effects (mild diarrhea, all in the erythromycin group). Etiological agents were identified in 41% of children. In conclusion, azithromycin is an effective therapeutic option for the treatment of community-acquired classic and atypical pneumonia in children. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12526069     DOI: 10.1002/ppul.10180

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  15 in total

1.  Reply to "how to diagnose Mycoplasma pneumoniae etiology in a child with pneumonia".

Authors:  Dan Xu; Shuxian Li; Zhimin Chen; Lizhong Du
Journal:  Eur J Pediatr       Date:  2011-10-07       Impact factor: 3.183

2.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 3.  Azithromycin for acute lower respiratory tract infections.

Authors:  Malinee Laopaiboon; Ratana Panpanich; Kyaw Swa Mya
Journal:  Cochrane Database Syst Rev       Date:  2015-03-08

Review 4.  Short-course therapy for community-acquired pneumonia in paediatric patients.

Authors:  Shamim Qazi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children.

Authors:  Anita L Kozyrskyj; Anita G Carrie; Garey B Mazowita; Lisa M Lix; Terry P Klassen; Barbara J Law
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

Review 6.  Antibiotics for community-acquired pneumonia in children.

Authors:  Rakesh Lodha; Sushil K Kabra; Ravindra M Pandey
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

7.  Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia.

Authors:  Joanna K Leyenaar; Meng-Shiou Shieh; Tara Lagu; Penelope S Pekow; Peter K Lindenauer
Journal:  Pediatr Infect Dis J       Date:  2014-04       Impact factor: 2.129

8.  Comparative Effectiveness of Beta-lactam Versus Macrolide Monotherapy in Children with Pneumonia Diagnosed in the Outpatient Setting.

Authors:  Lilliam Ambroggio; Matthew Test; Joshua P Metlay; Thomas R Graf; Mary Ann Blosky; Maurizio Macaluso; Samir S Shah
Journal:  Pediatr Infect Dis J       Date:  2015-08       Impact factor: 2.129

9.  Community-acquired pneumonia in children.

Authors:  H Dele Davies
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

Review 10.  Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia.

Authors:  Kay Wang; Peter Gill; Rafael Perera; Anne Thomson; David Mant; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.